Mobile

A 12 week, double-blind, randomized, parallel group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren 300 mg and hydrochlorothiazide 25 mg compared to aliskiren 30...

Mise à jour : Il y a 5 ans
Référence : EUCTR2008-000862-21

A 12 week, double-blind, randomized, parallel group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren 300 mg and hydrochlorothiazide 25 mg compared to aliskiren 300 mg in patients with Stage II hypertension

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare the BP lowering effect of the combination of aliskiren / HCTZ 300/25 mg versus aliskiren 300 mg monotherapy in patients with Stage II hypertension by testing the hypothesis that the combination of aliskiren / HCTZ produces a superior reduction from baseline in mean sitting systolic blood pressure (msSBP) after 12 weeks of treatment.

Critère d'inclusion

  • Hypertension

Liens